Bavarian Nordic Past Earnings Performance

Past criteria checks 5/6

Bavarian Nordic has been growing earnings at an average annual rate of 37.7%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 41.2% per year. Bavarian Nordic's return on equity is 10.5%, and it has net margins of 18.4%.

Key information

37.7%

Earnings growth rate

32.1%

EPS growth rate

Biotechs Industry Growth	11.5%
Revenue growth rate	41.2%
Return on equity	10.5%
Net Margin	18.4%
Next Earnings Update	05 Mar 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Bavarian Nordic makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BATS-CHIXE:BAVAC Revenue, expenses and earnings (DKK Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Sep 24	6,070	1,119	874	1,663
30 Jun 24	6,083	707	796	1,821
31 Mar 24	6,642	984	805	2,115
31 Dec 23	7,062	1,475	751	2,228
30 Sep 23	5,906	723	757	1,757
30 Jun 23	5,533	1,076	745	1,695
31 Mar 23	4,083	301	630	1,376
31 Dec 22	3,151	-347	589	1,183
30 Sep 22	2,404	-599	509	755
30 Jun 22	1,849	-693	484	470
31 Mar 22	1,683	-606	476	382
31 Dec 21	1,898	-465	485	399
30 Sep 21	1,583	-737	502	409
30 Jun 21	1,693	-629	542	437
31 Mar 21	2,022	-368	561	397
31 Dec 20	1,852	278	564	341
30 Sep 20	1,914	606	488	325
30 Jun 20	1,499	481	398	314
31 Mar 20	901	267	303	350
31 Dec 19	662	-347	227	387
30 Sep 19	554	-402	217	398
30 Jun 19	631	-271	211	379
31 Mar 19	616	-279	215	373
31 Dec 18	501	-362	214	386
30 Sep 18	360	-445	218	422
30 Jun 18	873	-151	209	511
31 Mar 18	1,184	5	206	535
31 Dec 17	1,370	181	208	518
30 Sep 17	1,745	453	205	512
30 Jun 17	1,463	225	214	482
31 Mar 17	1,182	153	211	459
31 Dec 16	1,007	31	213	463
30 Sep 16	909	-54	215	402
30 Jun 16	536	-202	204	349
31 Mar 16	808	-115	205	373
31 Dec 15	1,021	59	217	375
30 Sep 15	1,244	155	229	462
30 Jun 15	1,390	186	244	507
31 Mar 15	1,166	70	242	496
31 Dec 14	1,217	26	226	479
30 Sep 14	1,013	-99	204	425
30 Jun 14	1,107	-61	198	406
31 Mar 14	1,293	-12	198	512
31 Dec 13	1,213	-47	198	497

Quality Earnings: BAVAC has high quality earnings.

Growing Profit Margin: BAVAC's current net profit margins (18.4%) are higher than last year (12.2%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: BAVAC has become profitable over the past 5 years, growing earnings by 37.7% per year.

Accelerating Growth: BAVAC's earnings growth over the past year (54.6%) exceeds its 5-year average (37.7% per year).

Earnings vs Industry: BAVAC earnings growth over the past year (54.6%) exceeded the Biotechs industry -18.2%.

Return on Equity

High ROE: BAVAC's Return on Equity (10.5%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/19 09:26
End of Day Share Price	2024/11/19 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bavarian Nordic A/S is covered by 15 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Peter Ankersen	ABG Sundal Collier
Jacob Lademann	Carnegie Investment Bank AB
Peter Verdult	Citigroup Inc

Bavarian Nordic Past Earnings Performance

Past criteria checks 5/6

Key information

Recent past performance updates

Bavarian Nordic A/S to Report Fiscal Year 2024 Results on Mar 05, 2025

Full year 2022 earnings released: kr.4.90 loss per share (vs kr.7.37 loss in FY 2021)

Bavarian Nordic A/S to Report Fiscal Year 2022 Final Results on Mar 02, 2023

Third quarter 2021 earnings released: kr.1.30 loss per share (vs kr.0.50 profit in 3Q 2020)

First quarter 2021 earnings released

Recent updates

First Children Vaccinated in New Clinical Study Seeking to Expand the Indication for Bavarian Nordic's Mpox Vaccine

Bavarian Nordic A/S Upgrades Earnings Guidance for the Year 2024

Bavarian Nordic A/S Receives EMA Approval of Mpox Vaccine for Adolescents

Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine

Bavarian Nordic A/S Announces First Doses of its Mpox Vaccine, Mva-BN

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Singapore

Bavarian Nordic A/S, Annual General Meeting, Apr 09, 2025

Bavarian Nordic A/S to Report Fiscal Year 2024 Results on Mar 05, 2025

Bavarian Nordic A/S Submits Data to EMA to Extend Mpox/Smallpox Vaccine Approval to Adolescents

Bavarian Nordic A/S Receives Positive Chmp Opinion for Including Mpox Real-World Effectiveness Data in European Marketing Authorization for Smallpox and Mpox Vaccine

Bavarian Nordic A/S Receives EMA Filing Acceptance and Validation of the MAA for Its Chikungunya Vaccine

Bavarian Nordic A/S Submits Marketing Authorization Application for Its Chikungunya Vaccine Candidate to Ema

Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024

Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

Less than half of directors are independent

Less than half of directors are independent

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

Less than half of directors are independent

Less than half of directors are independent

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk

Bavarian Nordic A/S Reports Additional Phase 3 Results and Provides Update on Development Program for its cVLP-Based COVID-19 Booster Vaccine Candidate, ABNCoV2

Bavarian Nordic A/S, Annual General Meeting, Apr 16, 2024

Less than half of directors are independent

Bavarian Nordic A/S Provides Update on RSV Vaccine Program

Bavarian Nordic A/S Reports Data from A Phase 3 Clinical Trial of Its Vlp-Based Chikungunya Virus Vaccine in Adults >=65 Years of Age Study Successfully Met Its Primary Endpoints

Bavarian Nordic A/S Reports 12-Month Durability Data from Phase 2 Clinical Trial of Covid-19 Vaccine Candidate

Bavarian Nordic A/S acquired Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $384 million.

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Full year 2022 earnings released: kr.4.90 loss per share (vs kr.7.37 loss in FY 2021)

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S Provides Earnings Guidance for Fiscal Year 2023

Less than half of directors are independent

Bavarian Nordic A/S Provides Revenue Guidance for Fiscal Year 2022

Bavarian Nordic Completes Enrollment in Global Phase 3 Trial of RSV Vaccine Candidate for Older Adults

Chairman recently sold kr.508k worth of stock

Less than half of directors are independent

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic A/S Announces Covid-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial

Bavarian Nordic A/S Appoints Luc Debruyne as Board of Directors

Less than half of directors are independent

Bavarian Nordic A/S Revises Earnings Guidance for the Full Year 2022

Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its COVID-19 Booster Vaccine Candidate

Less than half of directors are independent

Bavarian Nordic A/S, Annual General Meeting, Mar 30, 2023

Bavarian Nordic A/S to Report Fiscal Year 2022 Final Results on Mar 02, 2023

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2022

Less than half of directors are independent

Bavarian Nordic A/S Receives U.S. and Eu Approvals of Its Fill and Finish Vaccine Manufacturing Facility

Bavarian Nordic A/S Receives Positive CHMP Opinion on the Extension of Vaccine Label to Include Monkeypox

Bavarian Nordic A/S Raises Earnings Guidance for the Financial Guidance for 2022

Less than half of directors are independent

Bavarian Nordic A/S Provides an Update on the Phase 3 Development of ABNCoV2, A VLP-Based, Non-Adjuvanted Covid-19 Booster Vaccine Candidate

Bavarian Nordic A/S Revises Revenue Guidance for the Year 2022

Bavarian Nordic A/S Raises Financial Guidance for the Year 2022

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic Reports Omicron Data from Phase 2 Trial of Its Covid-19 Booster Vaccine Candidate

Bavarian Nordic Announces Initiation of A Global Phase 3 Clinical Trial of Its RSV Vaccine Candidate in Older Adults

High number of new directors

Bavarian Nordic A/S Provides Revenue Guidance for the Full Year of 2022

Bavarian Nordic A/S Reports Additional Positive Phase 2 Results for Its Covid-19 Vaccine Candidate Ahead of Phase 3 Trial

Bavarian Nordic Announces Breakthrough Therapy Designation for Its RSV Vaccine Candidate for the Prevention of Respiratory Syncytial Virus in Older Adults

High number of new directors